Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | ATM | Q13315 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | SCN3A | Q9NY46 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | SCN1A | P35498 | 2/20 | 0.44 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pilsicainide SCHEMBL14809244 | 1.00 | KCNH2 (1.00) | KCNH2ATML3MBTL1POLBMEN1 | |
| Pilsicainide SCHEMBL483632 | 0.99 | KCNH2 (0.97) | KCNH2ATML3MBTL1POLBMEN1 | |
| Pilsicainide SCHEMBL1650876 | 0.97 | KCNH2 (0.95) | KCNH2ATML3MBTL1POLBMEN1 | |
| Pilsicainide SCHEMBL14471484 | 0.97 | KCNH2 (0.95) | KCNH2ATML3MBTL1POLBMEN1 | |
| Pilsicainide SCHEMBL483631 | 0.97 | KCNH2 (0.95) | KCNH2ATML3MBTL1POLBMEN1 | |
| SCHEMBL15551940 | 0.85 | KCNH2 (0.74) | KCNH2L3MBTL1POLBMEN1KMT2A | |
| SCHEMBL10840605 | 0.80 | KCNH2 (0.66) | KCNH2POLBKMT2ALMNAALDH1A1 | |
| SCHEMBL10371948 | 0.74 | KCNH2 (0.58) | KCNH2ATML3MBTL1POLBMEN1 | |
| Pyrrocaine SCHEMBL25718 | 0.72 | MEN1 (0.70) | KCNH2ATML3MBTL1POLBMEN1 | |
| SCHEMBL10372706 | 0.71 | ATM (0.57) | KCNH2ATML3MBTL1POLBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 978 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12117453-B2 | Predicting patient response to sodium channel blockers | WASHINGTON UNIVERSITY (US) | 2024-10-15 | — | — | US | claimed |
| US-20240074968-A1 | ORAL PHARMACEUTICAL COMPOSITION AND METHOD FOR PRODUCING PARTICULATE FORMULATION COMPRISING COMPOSITION | SUNSHO PHARMACEUTICAL CO LTD (JP) | 2024-03-07 | — | — | US | claimed |
| EP-4279137-A2 | ORAL PHARMACEUTICAL COMPOSITION AND METHOD FOR PRODUCING PARTICULATE FORMULATION COMPRISING COMPOSITION | Sunsho Pharmaceutical Co., Ltd. (JP) | 2023-11-22 | — | — | EP | claimed |
| EP-3485876-B1 | ORAL PHARMACEUTICAL COMPOSITION AND METHOD FOR PRODUCING PARTICULATE FORMULATION COMPRISING COMPOSITION | SUNSHO PHARMACEUTICAL CO LTD (JP) | 2023-11-22 | — | — | EP | claimed |
| US-20230201148-A1 | USES OF ORNITHINE PHENYLACETATE FOR TREATING HYPERAMMONEMIA | MALLINCKRODT LLC | 2023-06-29 | — | — | US | claimed |
| US-11685952-B2 | Biomarker for predicting risk of recurrence in patients with paroxysmal atrial fibrillation | KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION (KR) | 2023-06-27 | — | — | US | claimed |
| EP-4153162-A1 | USES OF ORNITHINE PHENYLACETATE FOR TREATING HYPERAMMONEMIA | Ocera Therapeutics, Inc. (US) | 2023-03-29 | — | — | EP | claimed |
| WO-2021236522-A1 | USES OF ORNITHINE PHENYLACETATE FOR TREATING HYPERAMMONEMIA | OCERA THERAPEUTICS, INC. (US) | 2021-11-25 | — | — | WO | claimed |
| US-20210313015-A1 | SPECIFICALLY-SHAPED CRYSTAL OF COMPOUND AND METHOD FOR PRODUCING SAME | TOWA PHARMACEUTICAL CO., LTD. (JP) | 2021-10-07 | — | — | US | claimed |
| US-20210228825-A1 | METHODS FOR DIAGNOSING BRUGADA SYNDROME USING AN AEROSOL | DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), AS COLLATERAL AGENT | 2021-07-29 | — | — | US | claimed |
| WO-2004056181-A1 | ORGAN PRECONDITIONING, ARREST, PROTECTION, PRESERVATION AND RECOVERY (2) | GLOBAL CARDIAC SOLUTIONS PTY LTD (AU) | 2004-07-08 | — | — | WO | claimed |
| WO-2004056180-A1 | ORGAN PRECONDITIONING, ARREST, PROTECTION, PRESERVATION AND RECOVERY (1) | GLOBAL CARDIAC SOLUTIONS PTY LTD (AU) | 2004-07-08 | — | — | WO | claimed |
| US-20040087513-A1 | New drug combinations based on sodium channel blockers and magnesium salts | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-05-06 | — | — | US | claimed |
| WO-2004019909-A2 | BUCCAL, POLAR AND NON-POLAR SPRAY OR CAPSULE CONTAINING CARDIOVASCULAR OR RENAL DRUGS | NOVADEL PHARMA INC. (US) | 2004-03-11 | — | — | WO | claimed |
| WO-2004004723-A1 | NOVEL MEDICAMENT COMBINATIONS BASED ON SODIUM CHANNEL BLOCKERS AND MAGNESIUM SALTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-01-15 | — | — | WO | claimed |
| US-20030235576-A1 | New drug combinations for the treatment of ischaemic conditions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-12-25 | — | — | US | claimed |
| WO-2003105844-A1 | MEDICAMENT COMBINATIONS OF SODIUM CHANNEL BLOCKERS AND FIBRINOLYTICS FOR TREATING ISCHAEMIC CONDITIONS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-12-24 | — | — | WO | claimed |
| US-20030077229-A1 | Buccal, polar and non-polar spray or capsule containing cardiovascular or renal drugs | NOVADEL PHARMA INC. | 2003-04-24 | — | — | US | claimed |
| EP-0089061-B1 | 8-SUBSTITUTED PYRROLIZIDINE DERIVATIVES AND USE THEREOF | SUNTORY KABUSHIKI KAISHA (JP) | 1987-12-16 | — | — | EP | claimed |
| US-4564624-A | 8-(Substituted N-phenylcarboxamidomethyl) pyrrolizidines and use thereof as antiarrhythmics | SUNTORY LTD. (JP) | 1986-01-14 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087513-A1 | New drug combinations based on sodium channel blockers and magnesium salts | CACNA1B, CACNA1C, CACNA1D | KCNH2 53/4885ATM 4593/4885L3MBTL1 4789/4885 |
| US-20210313015-A1 | SPECIFICALLY-SHAPED CRYSTAL OF COMPOUND AND METHOD FOR PRODUCING SAME | NOTUM, SOAT1, GYS2 | KCNH2 2037/4885ATM 2994/4885L3MBTL1 4856/4885 |
| US-20030235576-A1 | New drug combinations for the treatment of ischaemic conditions | SCN1B, CACNA1B, TNNI3 | KCNH2 34/4885ATM 4501/4885L3MBTL1 4643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.